Literature DB >> 29039528

lncRNA ROR promotes the proliferation of renal cancer and is negatively associated with favorable prognosis.

Jianguo Shi1, Wen Zhang2, Hongyang Tian3, Qiang Zhang3, Tongyi Men1.   

Abstract

Renal cell carcinoma (RCC) is one of the third most common types of urological cancer worldwide. Long non‑coding RNA (lncRNA) ROR has been reported to be important in regulating the malignant activities of different types of cancer, however, the function of lncRNA ROR in RCC remains to be fully elucidated. In order to investigate the function of lncRNA ROR in RCC, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis was used to detect the expression of lncRNA ROR in renal cancer tissues and adjacent tissues. Cell proliferation and apoptosis were determined using Cell Counting Kit-8 and apoptosis assays. Western blot analysis was used to measure the expression levels of c‑Myc and p53 following the suppression of lncRNA ROR in RCC cell lines. According to the results of the RT‑qPCR analysis, lncRNA ROR was found to be expressed at high levels in RCC tissues and cell lines. Patients with RCC exhibiting high expression levels of lncRNA ROR had shorter survival rates, compared with those with low expression levels of lncRNA ROR. The knockdown of lncRNA ROR resulted in a decrease of cell proliferation and increase of apoptosis in vitro. The suppression of lncRNA ROR also induced an increase in the expression of p53 and a decrease in the expression of c‑Myc in vitro. Taken together, these results demonstrated that lncRNA ROR was expressed at high levels in RCC tissue and cell lines, and was associated with the proliferation ability of RCC cells. These findings indicate that lncRNA ROR may be a promising therapeutic target for treating RCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29039528     DOI: 10.3892/mmr.2017.7775

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206.

Authors:  Dan Fei; Guoqing Sui; Yang Lu; Long Tan; Zhao Dongxu; Kewei Zhang
Journal:  J Cell Mol Med       Date:  2018-12-19       Impact factor: 5.310

2.  Prognostic value of long noncoding RNA ROR in patients with cancer in China: A systematic review and meta-analysis.

Authors:  Shuai Li; Xin-Can Yue; Chao-Yan Sun; Hai-Yan Qin; Xiao-Yang Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  lncRNA ROR promotes the progression of renal cell carcinoma through the miR‑206/VEGF axis.

Authors:  Jianguo Shi; Datian Zhang; Zhenhai Zhong; Wen Zhang
Journal:  Mol Med Rep       Date:  2019-09-02       Impact factor: 2.952

4.  linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.

Authors:  Yuanbiao Zhang; Weiding Wu; Qiang Sun; Longyun Ye; Dongkai Zhou; Weilin Wang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

5.  Clinicopathological and prognostic significance of long non-coding RNA-ROR in cancer patients: A systematic review and meta-analysis.

Authors:  Deqing Luo; Limin Yang; Le Yu; Yijin Chen; Zunxian Huang; Hui Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

6.  Long non-coding ROR promotes the progression of papillary thyroid carcinoma through regulation of the TESC/ALDH1A1/TUBB3/PTEN axis.

Authors:  Yuxia Fan; Xin Fan; Hao Yan; Zheng Liu; Xiaoming Wang; Qingling Yuan; Jie Xie; Xiubo Lu; Yang Yang
Journal:  Cell Death Dis       Date:  2022-02-16       Impact factor: 8.469

7.  Prognostic value of lncRNA ROR expression in various cancers: a meta-analysis.

Authors:  Renfu Lu; Junjian Chen; Lingwen Kong; Hao Zhu
Journal:  Biosci Rep       Date:  2018-09-28       Impact factor: 3.840

Review 8.  Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma.

Authors:  Huijie Zhang; Lei Yu; Jing Chen; Liting Liu; Xudong Yang; Hongwei Cui; Genquan Yue
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.